GlassScriptPhysician profile
Olga Colac
NPI 1245553015
$4,372.78
in general payments reported to CMS, 2019-2025
27 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $541 · 2022: $1,631 · 2023: $1,140 · 2024: $654 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,222.67 | 2021-2025 | Relistor |
| Ibsa Pharma INC. | $705.44 | 2021-2024 | Tirosint, Licart, Tirosint |
| Abbvie INC. | $659.08 | 2022-2025 | |
| Abbott Laboratories | $371.71 | 2021-2025 | Proclaim |
| Scilex Pharmaceuticals INC. | $305.76 | 2021-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $231.82 | 2022-2025 | Xtampza, Belbuca |
| Uswm, LLC | $147.00 | 2021-2023 | Zimhi, Lucemyra |
| Hikma Pharmaceuticals USA | $131.36 | 2022-2023 | Kloxxado |
| Arbor Pharmaceuticals, INC. | $69.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $64.54 | 2022-2023 | Seglentis |
| Azurity Pharmaceuticals, INC. | $57.70 | 2023-2025 | Horizant, Horizant |
| Pfizer INC. | $51.96 | 2021-2023 | |
| Nevro Corp. | $43.34 | 2022-2023 | Senza |
| Forte Bio-Pharma LLC | $35.06 | 2022 | |
| Bioventus LLC | $29.11 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $27.06 | 2022 | |
| Merz Pharmaceuticals, LLC | $25.52 | 2022 | |
| Masimo Corporation | $24.74 | 2023 | Patient Safetynet System |
| Saluda Medical Americas, INC. | $23.15 | 2024 | Evoke |
| Ferring Pharmaceuticals INC. | $22.80 | 2024 | Euflexxa |
| Medtronic, INC. | $20.53 | 2022 | |
| Fidia Pharma USA INC. | $18.96 | 2024 | Hymovis, Triluron, Hyalgan |
| Averitas Pharma INC. | $18.30 | 2024 | Qutenza |
| Almatica Pharma LLC | $17.83 | 2021 | |
| Redhill Biopharma INC. | $17.28 | 2022 | |
| Valinor Pharma, LLC | $15.54 | 2025 | Movantik |
| Amneal Pharmaceuticals LLC | $15.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Colac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.